Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.58 |
| ▸ | JAK2 | O60674 | 5/20 | 0.58 |
| ▸ | KDR | P35968 | 4/20 | 0.58 |
| ▸ | RET | P07949 | 3/20 | 0.58 |
| ▸ | CDC7 | O00311 | 1/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | INSR | P06213 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | ROS1 | P08922 | 1/20 | 0.58 |
| ▸ | FER | P16591 | 1/20 | 0.58 |
| ▸ | PRKACA | P17612 | 1/20 | 0.58 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | MARK3 | P27448 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503478 | 1.00 | SRC (0.58) | SRCJAK2KDRRETCDC7 | |
| SCHEMBL29588418 | 0.94 | EGFR (0.60) | SRCJAK2KDRRETCDC7 | |
| SCHEMBL31574063 | 0.94 | EGFR (0.60) | SRCJAK2KDRRETCDC7 | |
| SCHEMBL15345583 | 0.94 | EGFR (0.60) | SRCJAK2KDRRETCDC7 | |
| SCHEMBL14706373 | 0.94 | EGFR (0.60) | SRCJAK2KDRRETCDC7 | |
| SCHEMBL29799663 | 0.94 | EGFR (0.60) | SRCJAK2KDRRETCDC7 | |
| SCHEMBL4824842 | 0.94 | EGFR (0.60) | SRCJAK2KDRRETCDC7 | |
| SCHEMBL15705842 | 0.92 | SRC (0.57) | SRCJAK2KDRRETCDC7 | |
| SCHEMBL22835195 | 0.92 | SRC (0.57) | SRCJAK2KDRRETCDC7 | |
| SCHEMBL29573937 | 0.92 | SRC (0.57) | SRCJAK2KDRRETCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3788050-B1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | FLASH THERAPEUTICS, LLC (US) | 2024-04-23 | — | — | US | disclosed |
| CN-115304606-B | Degradation agent for simultaneously targeting BTK and GSPT proteins | 清华大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-112368289-B | C26-linked rapamycin analogues as MTOR inhibitors | 锐新医药公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11833153-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-12-05 | — | — | US | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | SRC 2167/4885JAK2 1515/4885KDR 836/4885 |
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | MCL1, FLT3, ABL1 | SRC 95/4885JAK2 131/4885KDR 2025/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | SRC 971/4885JAK2 803/4885KDR 3263/4885 |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | SRC 971/4885JAK2 803/4885KDR 3263/4885 |
| US-11833153-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | ATF4, MAP3K1, MAP3K6 | SRC 161/4885JAK2 424/4885KDR 2509/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | SRC 715/4885JAK2 642/4885KDR 2576/4885 |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | SRC 715/4885JAK2 642/4885KDR 2576/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | SRC 1785/4885JAK2 1175/4885KDR 3134/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | SRC 1834/4885JAK2 1212/4885KDR 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.